Postoperative hyperprolactinemia could predict longer disease-free and overall survival in node-negative breast cancer patients

被引:8
作者
Mandalà, M
Lissoni, P
Ferretti, G
Rocca, A
Torri, V
Moro, C
Curigliano, G
Barni, S
机构
[1] Treviglio Hosp, Div Med Oncol, I-24047 Treviglio, Italy
[2] Osped San Gerardo, Div Radiat Oncol, Monza, Italy
[3] S Maria Goretti Hosp, Div Med Oncol, Latina, Italy
[4] European Inst Oncol, Div Med Oncol, Milan, Italy
[5] Ist Ric Farmacol Mario Negri, Div Stat, Milan, Italy
[6] Fdn Salvatore Maugeri, Pavia, Italy
关键词
hyperprolactinemia; breast cancer; node-negative;
D O I
10.1159/000066228
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Breast manipulation determines a physiological increase in prolactin (PRL) blood levels, but the clinical and biological impact of surgery-induced changes in PRL secretion still has to be clarified. The postoperative hyperprolactinemia has been related to aggressiveness of the tumor, early disease relapse or metastases, and poor overall survival in node-negative breast cancer patients. Surgery-induced hyperprolactinemia may be associated with a longer disease-free survival in both patients with or without node involvement. Methods: One hundred twenty-seven consecutive node-negative breast cancer patients, who were hospitalized from June 1985 to September 1990, were included in this study. The median follow-up was 12 years. To evaluate PRL secretion, venous blood samples were obtained at day 7th after surgery. In order to exclude the influence of stress and gonadal status, GH and estradiol serum levels were measured in the same blood samples. All endocrine examination were made during the morning, starting at 8.00 a.m. after overnight fasting. Hormonal serum levels were determined by the double antibody radioimmunoassay method. Results: Hyperprolactinemia was significantly more frequent in women younger than 50 years compared with the older ones, while the premenopausal status and T1 stage showed only a borderline significant association with hyperprolactinemia. Patients with normal postsurgical prolactinemia had 5- and 10-year disease-free survival rates of 64 and 56%, respectively, and 5- and 10-year overall survival rates of 84 and 70%, respectively. Patients with postsurgical hyperprolactinemia had 5- and 10-year disease-free survival rates of 89 and 81%, respectively, and 5- and 10-year overall survival rates of 94 and 81%, respectively. The difference in overall survival between the hyperprolactinemic and the normoprolactinemic groups, assessed by the logrank test, was statistically significant (p = 0.02), and the difference in disease-free survival was highly significant (p = 0.0008). Conclusions: Our study shows that postsurgical hyperprolactinemia is associated with a significantly lower recurrence rate and longer disease-free and overall survival in operable node-negative breast cancer patients. Our data suggest that postoperative hyperprolactinernia could be crucial in the development of recur-
引用
收藏
页码:370 / 377
页数:8
相关论文
共 24 条
[1]  
[Anonymous], 1998, LANCET, V351, P1451
[2]   PROGNOSTIC FACTORS AND NATURAL-HISTORY IN LYMPH NODE-NEGATIVE BREAST-CANCER PATIENTS [J].
ARRIAGADA, R ;
RUTQVIST, LE ;
SKOOG, L ;
JOHANSSON, H ;
KRAMAR, A .
BREAST CANCER RESEARCH AND TREATMENT, 1992, 21 (02) :101-109
[3]   SERUM LEVELS OF INSULIN-LIKE GROWTH-FACTOR-I IN OPERABLE BREAST-CANCER IN RELATION TO THE MAIN PROGNOSTIC VARIABLES AND THEIR PERIOPERATIVE CHANGES IN RELATION TO THOSE OF PROLACTIN [J].
BARNI, S ;
LISSONI, P ;
BRIVIO, F ;
FUMAGALLI, L ;
MERLINI, D ;
CATALDO, M ;
ROVELLI, F ;
TANCINI, G .
TUMORI, 1994, 80 (03) :212-215
[4]  
BHATAVDEKAR JM, 1994, ONCOL REP, V1, P841
[5]  
BOYNS AR, 1973, EUR J CANCER, V9, P169
[6]  
CLARK GM, 1988, SEMIN ONCOL, V15, P20
[7]   RELATIVE WORTH OF ESTROGEN OR PROGESTERONE-RECEPTOR AND PATHOLOGIC CHARACTERISTICS OF DIFFERENTIATION AS INDICATORS OF PROGNOSIS IN NODE NEGATIVE BREAST-CANCER PATIENTS - FINDINGS FROM NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT PROTOCOL B-06 [J].
FISHER, B ;
REDMOND, C ;
FISHER, ER ;
CAPLAN, R .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (07) :1076-1087
[8]   Should prolactin be reconsidered as a therapeutic target in human breast cancer? [J].
Goffin, V ;
Touraine, P ;
Pichard, C ;
Bernichtein, S ;
Kelly, PA .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1999, 151 (1-2) :79-87
[9]  
Gordts SL, 2000, EUR J CANCER, V36, pS20
[10]   COMPARATIVE-EVALUATION OF ER-ICA AND ENZYME-IMMUNOASSAY FOR THE QUANTITATION OF ESTROGEN-RECEPTORS IN BREAST-CANCER [J].
HANNA, W ;
MOBBS, BG .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1989, 91 (02) :182-186